Less than a week after Eisai secured a full approval for Leqembi — the first Alzheimer's drug to achieve full approval — the drugmaker's CEO announced his plan to retire by the end of July.
Ivan Cheung, the CEO, president, senior vice president and chair of Eisai, will retire by July 31, according to a July 11 news release. Five executives were promoted, including Tatsuyuki Yasuno, who was CFO and is now acting president of the Americas and CEO and senior vice president of Eisai.